학술논문
1318MO First-in-human study of ABBV-637, an EGFR-targeting BCL-XL–inhibiting antibody-drug conjugate combined with osimertinib (OSI) in relapsed/refractory, EGFR-mutated non-small cell lung cancer (NSCLC)
Document Type
Abstract
Author
Source
In Annals of Oncology October 2023 34 Supplement 2:S759-S759
Subject
Language
ISSN
0923-7534